NORD comments to FDA regarding patient preferences in device development
Published: Jul 1, 2019
Tagged in: Access to Innovative Medicines and Therapies, Patient Focused Drug Development
For decades, NORD has pursued federal and state policies that will change the lives of Americans impacted by rare diseases for the better. NORD’s work can be viewed below. This page is updated daily to provide timely information. Please contact us if you have questions or need additional information.
NORD comments to FDA regarding patient preferences in device development
Published: Jul 1, 2019
Tagged in: Access to Innovative Medicines and Therapies, Patient Focused Drug Development
NORD comments to FDA regarding natural history data registries
Published: May 24, 2019
Tagged in: Access to Innovative Medicines and Therapies, Patient Focused Drug Development
NORD comments to FDA on common issues in rare disease drug development
Published: Apr 2, 2019
Tagged in: Access to Innovative Medicines and Therapies, Patient Focused Drug Development
NORD comments to FDA regarding submitting guidance on Patient Experience Data (PED)
Published: Mar 21, 2019
Tagged in: Access to Innovative Medicines and Therapies, Patient Focused Drug Development
NORD comments to FDA on the Framework for the Real-World Evidence Program
Published: Feb 5, 2019
Tagged in: Access to Innovative Medicines and Therapies, Patient Focused Drug Development
NORD comments to the Food and Drug Administration (FDA) regarding a patient engagement in medical device clinical trials discussion document
Published: Jan 8, 2019
Tagged in: Access to Innovative Medicines and Therapies, Patient Focused Drug Development